Pharma Expanse is a leading provider of contract development and manufacturing services for pharmaceutical and biotech companies. Pharma Expanse is partnered with multiple Contract Development & Manufacturing Organizations (CDMOs) supporting manufacturing of RSMs, APIs, Oral Solid Dosages, Sterile Injectable drug products, and cell therapies. Pharma Expanse has drug product capabilities across a number of modalities including small molecules, biologics, ADCs, peptides, and nucleic acids (mRNA). Cell Therapy capabilities include cell line development, master cell banking and GMP manufacturing of allogeneic induced Pluripotent Stem Cells (iPSCs) for oncology and regenerative medicine.

The Pharma Expanse network currently spans across 20 manufacturing sites in 8 countries and can support discovery, preclinical, clinical, and commercial programs for New Chemical Entities (NCEs). Pharma Expanse operates as an integral part of the CDMO teams and is not a broker/agent. Pharma Expanse has an innovative business model that does not add additional costs to your project. Save your valuable time by streamlining your interactions with Pharma Expanse. 

Get in touch with Pharma Expanse to discuss development and manufacturing capabilities for your clinical and commercial programs or to request a proposal for manufacturing. Simplify outsourcing with Pharma Expanse! Contact us at info@PharmaExpanse.com to schedule a meeting.

For Pharma pipeline assets, Pharma Expanse is also working with a clinical stage, anti-infective and women’s health company that is developing first-in-class therapeutics with novel mechanisms of action to treat multidrug resistant pathogens. The lead molecule completed Phase 1 clinical trials in June of 2025, and initiated Phase 2 clinical trials in June of 2026. The drug has already received FDA Fast Track and QIDP designations.